NCT03291028
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Active, Not Recruiting
Not specifiedAll AgesObservationalFox Chase Cancer CenterInvestigator-initiated
~15 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:Immune checkpoint inhibitor targeting PD1
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Histopathological characterization of samples from ICB treated patients
Measured over 18 months
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Eligible patients will include retrospectively identified patients with RCC or UC who have received treatment with ICB and achieved clinical benefit but subsequently developed a solitary new/progressive lesion that was removed surgically. Patients with other tumor types who otherwise meet criteria may be included at a later time
Additionally, a group of patients with RCC who have undergone a metastasectomy but who did not receive treatment with ICB will be identified. These patients may be approached for study participation to serve as a comparator group
What this trial measures
- Histopathological characterization of samples from ICB treated patients18 months
To characterize differences in histopathology and patterns of genomic expression between baseline tumors and metastases exhibiting divergent growth kinetics ("escape" metastases) in patients treated with immune checkpoint blockade (ICB)
- Genomic characterization of samples from ICB treated patients18 months
To characterize expression of different genes between baseline tumors and metastases exhibiting divergent growth kinetics ("escape" metastases) in patients treated with immune checkpoint blockade (ICB)